Colorectal serrated pathway cancers and precursors

Histopathology

Volumn 66, Issue 1, 2015, Pages 49-65

  O'Brien, Michael J ^a   Zhao, Qing ^a   Yang, Shi ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF; CIMP; Colorectal carcinoma; Hyperplastic polyp; KRAS; Microsatellite instability; Molecular pathology; Serrated carcinoma; Sessile serrated adenoma; Sessile serrated lesion; Traditional serrated adenoma

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MOLECULAR MARKER; MUCIN 5AC; MUCIN 6; RAF PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR CDX2;

CANCER CLASSIFICATION; CANCER MORTALITY; CANCER SURVIVAL; CELL PROLIFERATION; COLORECTAL CANCER; CPG ISLAND; DNA REPAIR; DYSPLASIA; GENE MUTATION; GENETIC COUNSELING; HISTOPATHOLOGY; HUMAN; MEDULLARY CARCINOMA; MISMATCH REPAIR; MOLECULAR GENETICS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRECURSOR; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECTUM ADENOMA; RECTUM INJURY; REVIEW; SIGNAL TRANSDUCTION; ADENOMA; COLORECTAL TUMOR; GENETICS; PATHOLOGY; PRECANCER;

ADENOMA; COLORECTAL NEOPLASMS; HUMANS; PRECANCEROUS CONDITIONS;

EID: 84920996896     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12564     Document Type: Review

References (110)

1. Bettington M, Walker N, Clouston A et al. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology 2013; 62; 367-386.
2. Rex DK, Ahnen DJ, Baron JA et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am. J. Gastroenterol. 2012; 107; 1315-1329.
3. Chen D, Huang JF, Liu K et al. BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS ONE 2014; 9; e90607.
4. Clancy C, Burke JP, Kalady MF et al. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis. Colorectal Dis. 2013; 15; e711-e718.
5. Vaughn CP, Zobell SD, Furtado LV et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosom. Cancer 2011; 50; 307-312.
6. Ogino S, Kawasaki T, Kirkner GJ et al. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J. Mol. Diagn. 2006; 8; 582-588.
7. O'Brien MJ, Yang S, Mack C et al. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am. J. Surg. Pathol. 2006; 30; 1491-1501.
8. Burnett-Hartman AN, Newcomb PA, Potter JD et al. Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas. Cancer Res. 2013; 73; 2863-2872.
9. Stefanius K, Ylitalo L, Tuomisto A et al. Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma. Histopathology 2011; 58; 679-692.
10. Samadder NJ, Curtin K, Tuohy TM et al. Characteristics of missed or interval colorectal cancer and patient survival: a population-based study. Gastroenterology 2014; 146; 950-960.
11. Pohl H, Srivastava A, Bensen SP et al. Incomplete polyp resection during colonoscopy - results of the complete adenoma resection (CARE) study. Gastroenterology 2013; 144; 74-80 e1.
12. Sawhney MS, Farrar WD, Gudiseva S et al. Microsatellite instability in interval colon cancers. Gastroenterology 2006; 131; 1700-1705.
13. Arain MA, Sawhney M, Sheikh S et al. CIMP status of interval colon cancers: another piece to the puzzle. Am. J. Gastroenterol. 2010; 105; 1189-1195.
14. Pai RK, Jayachandran P, Koong AC et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am. J. Surg. Pathol. 2012; 36; 744-752.
15. Ogino S, Nosho K, Kirkner GJ et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58; 90-96.
16. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 2010; 138; 2088-2100.
17. Huang CS, Farraye FA, Yang S et al. The clinical significance of serrated polyps. Am. J. Gastroenterol. 2011; 106; 229-240.
18. Walsh MD, Clendenning M, Williamson E et al. Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. Mod. Pathol. 2013; 26; 1642-1656.
19. Hartman DJ, Brand RE, Hu H et al. Lynch syndrome-associated colorectal carcinoma: frequent involvement of the left colon and rectum and late-onset presentation supports a universal screening approach. Hum. Pathol. 2013; 44; 2518-2528.
20. Makinen MJ. Colorectal serrated adenocarcinoma. Histopathology 2007; 50; 131-150.
21. Tuppurainen K, Makinen JM, Junttila O et al. Morphology and microsatellite instability in sporadic serrated and non-serrated colorectal cancer. J. Pathol. 2005; 207; 285-294.
22. Hamilton SR, Bosman FT, Boffetta P et al. Carcinoma of the colon and rectum. Bosman FT, Carneiro F, Hruban RH, Theise ND eds. WHO classification of tumors of the digestive system. Lyon, France: IARC, 2010; 134-146.
23. Lochhead P, Kuchiba A, Imamura Y et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J. Natl Cancer Inst. 2013; 105; 1151-1156.
24. Garcia-Solano J, Conesa-Zamora P, Carbonell P et al. Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas. Int. J. Cancer 2012; 131; 1790-1799.
25. Young J, Simms LA, Biden KG et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am. J. Pathol. 2001; 159; 2107-2116.
26. Antelo M, Balaguer F, Shia J et al. A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. PLoS ONE 2012; 7; e45357.
27. Landau MS, Kuan SF, Chiosea S et al. BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression. Hum. Pathol. 2014; 45; 1704-1712.
28. Wick MR, Vitsky JL, Ritter JH et al. Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma. Am. J. Clin. Pathol. 2005; 123; 56-65.
29. Nguyen J, Coppola D, Shan Y et al. Poorly differentiated medullary carcinoma of the colon with an unusual phenotypic profile mimicking high grade large cell lymphoma - a unique case report and review of the literature. Int. J. Clin. Exp. Pathol. 2014; 7; 828-834.
30. Remo A, Zanella C, Molinari E et al. Rhabdoid carcinoma of the colon: a distinct entity with a very aggressive behavior: a case report associated with a polyposis coli and review of the literature. Int. J. Surg. Pathol. 2012; 20; 185-190.
31. Hinoi T, Tani M, Lucas PC et al. Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am. J. Pathol. 2001; 159; 2239-2248.
32. Samowitz WS, Sweeney C, Herrick J et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005; 65; 6063-6069.
33. Ogino S, Shima K, Meyerhadt JA et al. Predictive and prognostic roles of BRAF mutation I Stage III colon cancer: results from intergroup trial CALGB 89803. Clin. Cancer Res. 2012; 18; 890-900.
34. Ogino S, Kawasaki T, Kirkner GJ et al. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut 2007; 56; 1564-1571.
35. Mouradov D, Domingo E, Gibbs P et al. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am. J. Gastroenterol. 2013; 108; 1785-1793.
36. Imamura Y, Morikawa T, Liao X et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin. Cancer Res. 2012; 18; 4753-4763.
37. Rosty C, Young JP, Walsh MD et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod. Pathol. 2013; 26; 825-834.
38. Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487; 330-337.
39. Shima K, Morikawa T, Yamauchi M et al. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers. PLoS ONE 2011; 6; e25062.
40. Brady CA, Attardi LD. p53 at a glance. J. Cell Sci. 2010; 123; 2527-2532.
41. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50; 113-130.
42. O'Brien MJ. Hyperplastic and serrated polyps of the colorectum. Gastroenterol. Clin. North Am. 2007; 36; 947-968, viii.
43. Heald B, Plesec T, Liu X et al. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J. Clin. Oncol. 2013; 31; 1336-1340.
44. Kim GP, Colangelo LH, Wieand HS et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J. Clin. Oncol. 2007; 25; 767-772.
45. Shen L, Catalano PJ, Benson AB III et al. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin. Cancer Res. 2007; 13; 6093-6098.
46. Hampel H, Frankel WL, Martin E et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N. Engl. J. Med. 2005; 352; 1851-1860.
47. Toon CW, Walsh MD, Chou A et al. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am. J. Surg. Pathol. 2013; 37; 1592-1602.
48. Thiel A, Heinonen M, Kantonen J et al. BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Arch. 2013; 463; 613-621.
49. Perez-Carbonell L, Alenda C, Paya A et al. Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome. J. Mol. Diagn. 2010; 12; 498-504.
50. Gausachs M, Mur P, Corral J et al. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. Eur. J. Hum. Genet. 2012; 20; 762-768.
51. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2003; 349; 247-257.
52. Day FL, Jorissen RN, Lipton L et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin. Cancer Res. 2013; 19; 3285-3296.
53. Rosty C, Young JP, Walsh MD et al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS ONE 2013; 8; e65479.
54. Torlakovic E, Skovlund E, Snover DC et al. Morphologic reappraisal of serrated colorectal polyps. Am. J. Surg. Pathol. 2003; 27; 65-81.
55. Torlakovic E, Snover DC. Serrated adenomatous polyposis in humans. Gastroenterology 1996; 110; 748-755.
56. Snover DC, Ahnen DJ, Burt RW et al. Serrated polyps of the colon and rectum and serrated polyposis. In Bosman FT, Carneiro F, Hruban RH, Theise ND eds. WHO classification of tumors of the digestive system, 4th edn. Lyon, France: IACR, 2010; 160-165.
57. Bateman AC, Shepherd NA, British Society of Gastroenterology, Serrated Lesion Working Group. Serrated lesions-nomenclature. 2014; in press.
58. Kahi CJ, Li X, Eckert GJ et al. High colonoscopic prevalence of proximal colon serrated polyps in average-risk men and women. Gastrointest. Endosc. 2012; 75; 515-520.
59. Hetzel JT, Huang CS, Coukos JA et al. Variation in the detection of serrated polyps in an average risk colorectal cancer screening cohort. Am. J. Gastroenterol. 2010; 105; 2656-2664.
60. Payne SR, Church TR, Wandell M et al. Endoscopic detection of proximal serrated lesions and pathologic identification of sessile serrated adenomas/polyps vary on the basis of center. Clin. Gastroenterol. Hepatol. 2014; 12; 1119-1126.
61. Gill P, Wang LM, Bailey A et al. Reporting trends of right-sided hyperplastic and sessile serrated polyps in a large teaching hospital over a 4-year period (2009-2012). J. Clin. Pathol. 2013; 66; 655-658.
62. East JE. Proximal serrated polyp detection at colonoscopy: the best of times. the worst of times? Gastrointest. Endosc. 2012; 75; 521-524.
63. East JE, Saunders BP, Jass JR. Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: classification, molecular genetics, natural history, and clinical management. Gastroenterol. Clin. North Am. 2008; 37; 25-46, v.
64. Spring KJ, Zhao ZZ, Karamatic R et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology 2006; 131; 1400-1407.
65. Tadepalli US, Feihel D, Miller KM et al. A morphologic analysis of sessile serrated polyps observed during routine colonoscopy (with video). Gastrointest. Endosc. 2011; 74; 1360-1368.
66. Mochizuka A, Uehara T, Nakamura T et al. Hyperplastic polyps and sessile serrated 'adenomas' of the colon and rectum display gastric pyloric differentiation. Histochem. Cell Biol. 2007; 128; 445-455.
67. Gibson JA, Hahn HP, Shahsafaei A et al. MUC expression in hyperplastic and serrated colonic polyps: lack of specificity of MUC6. Am. J. Surg. Pathol. 2011; 35; 742-749.
68. Kimura T, Yamamoto E, Yamano HO et al. A novel pit pattern identifies the precursor of colorectal cancer derived from sessile serrated adenoma. Am. J. Gastroenterol. 2012; 107; 460-469.
69. Torlakovic EE, Gomez JD, Driman DK et al. Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA). Am. J. Surg. Pathol. 2008; 32; 21-29.
70. Chung SM, Chen YT, Panczykowski A et al. Serrated polyps with 'intermediate features' of sessile serrated polyp and microvesicular hyperplastic polyp: a practical approach to the classification of nondysplastic serrated polyps. Am. J. Surg. Pathol. 2008; 32; 407-412.
71. Mohammadi M, Garbyal RS, Kristensen MH et al. Sessile serrated lesion and its borderline variant - variables with impact on recorded data. Pathol. Res. Pract. 2011; 207; 410-416.
72. Lash RH, Genta RM, Schuler CM. Sessile serrated adenomas: prevalence of dysplasia and carcinoma in 2139 patients. J. Clin. Pathol. 2010; 63; 681-686.
73. Bettington M, Walker N, Rosty C et al. Critical appraisal of the diagnosis of the sessile serrated adenoma. Am. J. Surg. Pathol. 2014; 38; 158-166.
74. Rosenberg DW, Yang S, Pleau DC et al. Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res. 2007; 67; 3551-3554.
75. Kambara T, Simms LA, Whitehall VL et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004; 53; 1137-1144.
76. Burnett-Hartman AN, Newcomb PA, Phipps AI et al. Colorectal endoscopy, advanced adenomas, and sessile serrated polyps: implications for proximal colon cancer. Am. J. Gastroenterol. 2012; 107; 1213-1219.
77. Yang S, Farraye FA, Mack C et al. BRAF and KRAS mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am. J. Surg. Pathol. 2004; 28; 1452-1459.
78. Huang CS, O'Brien MJ, Yang S et al. Hyperplastic polyps, serrated adenomas, and the serrated polyp neoplasia pathway. Am. J. Gastroenterol. 2004; 99; 2242-2255.
79. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 2009; 9; 400-414.
80. Kriegl L, Neumann J, Vieth M et al. Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod. Pathol. 2011; 24; 1015-1022.
81. Gala MK, Mizukami Y, Le LP et al. Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. Gastroenterology 2014; 146; 520-529.
82. Salama R, Sadaie M, Hoare M et al. Cellular senescence and its effector programs. Genes Dev. 2014; 28; 99-114.
83. Sheridan TB, Fenton H, Lewin MR et al. Sessile serrated adenomas with low- and high-grade dysplasia and early carcinomas: an immunohistochemical study of serrated lesions 'caught in the act'. Am. J. Clin. Pathol. 2006; 126; 564-571.
84. Goldstein N. Small colonic microsatellite unstable adenocarcinomas and high-grade epithelial dysplasias in sessile serrated adenoma polypectomy specimens. Am. J. Clin. Pathol. 2006; 125; 132-145.
85. Suzuki H, Watkins DN, Jair KW et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 2004; 36; 417-422.
86. Fu X, Li L, Peng Y. Wnt signalling pathway in the serrated neoplastic pathway of the colorectum: possible roles and epigenetic regulatory mechanisms. J. Clin. Pathol. 2012; 65; 675-679.
87. Loh K, Chia JA, Greco S et al. Bone morphogenic protein 3 inactivation is an early and frequent event in colorectal cancer development. Genes Chromosom. Cancer 2008; 47; 449-460.
88. Ito M, Mitsuhashi K, Igarashi H et al. MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions. Int. J. Cancer 2014; 135; 2507-2515.
89. Schmitz KJ, Hey S, Schinwald A et al. Differential expression of microRNA 181b and microRNA 21 in hyperplastic polyps and sessile serrated adenomas of the colon. Virchows Arch. 2009; 455; 49-54.
90. Caruso M, Moore J, Goodall GJ et al. Over-expression of cathepsin E and trefoil factor 1 in sessile serrated adenomas of the colorectum identified by gene expression analysis. Virchows Arch. 2009; 454; 291-302.
91. Delker DA, McGettigan BM, Kanth P et al. RNA sequencing of sessile serrated colon polyps identifies differentially expressed genes and immunohistochemical markers. PLoS ONE 2014; 9; e88367.
92. Gonzalo DH, Lai KK, Shadrach B et al. Gene expression profiling of serrated polyps identifies annexin A10 as a marker of a sessile serrated adenoma/polyp. J. Pathol. 2013; 230; 420-429.
93. Pai RK, Shadrach BL, Carver P et al. Immunohistochemistry for annexin A10 can distinguish sporadic from Lynch syndrome-associated microsatellite-unstable colorectal carcinoma. Am. J. Surg. Pathol. 2014; 38; 518-525.
94. O'Brien MJ, Winawer SJ, Zauber AG et al. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990; 98; 371-379.
95. Konishi F, Morson BC. Pathology of colorectal adenomas: a colonoscopic survey. J. Clin. Pathol. 1982; 35; 830-841.
96. Fujita K, Yamamoto H, Matsumoto T et al. Sessile serrated adenoma with early neoplastic progression: a clinicopathologic and molecular study. Am. J. Surg. Pathol. 2011; 35; 295-304.
97. Longacre TA, Fenoglio-Preiser CM. Mixed hyperplastic adenomatous polyps/serrated adenomas. A distinct form of colorectal neoplasia. Am. J. Surg. Pathol. 1990; 14; 524-537.
98. Yantiss RK, Oh KY, Chen YT et al. Filiform serrated adenomas: a clinicopathologic and immunophenotypic study of 18 cases. Am. J. Surg. Pathol. 2007; 31; 1238-1245.
99. Ha SY, Lee SM, Lee EJ et al. Filiform serrated adenoma is an unusual, less aggressive variant of traditional serrated adenoma. Pathology 2012; 44; 18-23.
100. Jass JR, Baker K, Zlobec I et al. Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a 'fusion' pathway to colorectal cancer. Histopathology 2006; 49; 121-131.
101. Kim KM, Lee EJ, Kim YH et al. KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype. Am. J. Surg. Pathol. 2010; 34; 667-675.
102. Tsai JH, Liau JY, Lin YL et al. Traditional serrated adenoma has two pathways of neoplastic progression that are distinct from the sessile serrated pathway of colorectal carcinogenesis. Mod. Pathol. 2014; 27; 1375-1385.
103. Kim CK, Nguyen TL, Joo KM et al. Negative regulation of p53 by the long isoform of ErbB3 binding protein Ebp1 in brain tumors. Cancer Res. 2010; 70; 9730-9741.
104. Patil DT, Shadrach BL, Rybicki LA et al. Proximal colon cancers and the serrated pathway: a systematic analysis of precursor histology and BRAF mutation status. Mod. Pathol. 2012; 25; 1423-1431.
105. Wiland HO, Shadrach B, Allende D et al. Morphological and molecular characterization of traditional serrated adenoma of the distal colon and rectum. Am. J. Surg. Pathol. 2014; 38; 1290-1297.
106. Fu B, Yachida S, Morgan R et al. Clinicopathologic and genetic characterization of traditional serrated adenomas of the colon. Am. J. Clin. Pathol. 2012; 138; 356-366.
107. Bennecke M, Kriegl L, Bajbouj M et al. Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell 2010; 18; 135-146.
108. Carragher LA, Snell KR, Giblett SM et al. V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol. Med. 2010; 2; 458-471.
109. Minoo P. Toward a molecular classification of colorectal cancer: the role of MGMT. Front. Oncol. 2013; 3; 266.
110. Whitehall VL, Walsh MD, Young J et al. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res. 2001; 61; 827-830.